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ABSTRACT
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l
ZA-DISULFO PHENYL BUTYL NITRONE,
ITS SALTS AND THEIR USE AS

PHARMACEUTICALS
CONTINUING DATA
Y

This application is a continuation-in-part (CIP) of Ser. No.
08/173579. ?led on Dec. 23. 1993. now US. Pat. No.

and n is a whole integer from 1 to 5 or

5.488.145.
BACKGROUND OF THE INVENTION
This invention relates to a particular nitrone compound
and its salts and their advantageous use as pharmaceutical

nitrone free radical trapping agents.
Alpha-phenyl tert butyl nitrone

and Y is tert-butyl or a hydroxylated or acetylated tert-butyl
or a substituted phenyl. These compounds were proposed as
pharmaceutical agents to treat the aftermath of stroke and
other conditions reported to be associated with free radical

damage.
20

In 1992 a second PCT patent application was ?led
directed to PBN and related compounds and their medical

use. This application. based on prior US. patent application
Ser. No. 716.952 (?led Jun. 18. 1991). was published on
Dec. 23. 1992 as WO 92/22290. This 1992 publication

or “PBN”) was identi?ed in the 1970s as a useful analytical

reagent to be used in conjunction with electron spin reso
nance (“ESR") to aid in the detection of free radicals. PBN

provided two extremely broad and general disclosures. First.

was found to react with certain free radicals and generate a

chemical species yielding a characteristic ESR spectrum and

it attempted to describe as many disease states as possible
which were associated with free radicals. These ranged from

thus making it possible to determine the presence or absence
of free radicals.

CNS conditions (including stroke. aging. migraine. etc.)
through peripheral organ disease (including atherosclerosis.

In the late 1970s and early 1980s the medical community
began to focus on the roles played by free radicals in

exposure. to mention but a few highlights. Second. it

diseases such as heart attacks. strokes and the like. PBN was

attempted to list as many potential spin traps as possible.

bed sores. wounds. and muscle overexertion) through UV

used increasingly in vitro to provide analytical evidence of

In addition to a Whole range of non-PBN materials. this

the presence of free radicals in these settings. It was also
later administered in vivo in animal models. again as an

application greatly expanded the de?nition of potentially
35

analytical adjunct in attempts to observe free radicals during

useful PBN compounds to include PBN. and derivatives
thereof of the formula

ischemia simulations and the like.

In the mid 1980s. the ?rst possible therapeutic effects of
PBN were implied when severe trauma ischemia animal
tests showed that PEN-treated animals were more likely to 40

survive than controls.

On May 2. 1991. PCI‘ patent application WO-91-05552
was published. This patent application. which in part cor
responds to now-issued US. Pat. Nos. 5.825.032 and 5.036.

wherein

X is phenyl. imidazolyl. phenothiazinyl or

097. described PBN and a family of PBN derivatives de?ned

by the formula

(R2).
H

O’
C=N+

50

X

Y

n=1—5. preferably 1-3;
R2=independently (can vary within the molecule)

wherein
X is phenyl or

halogen. alkyl. oxyalkyl. alkenyl. oxyalkenyl. OH.
NH2. NHZ. NZ2. NO.
(0R),

where R is H.
0

ll
Z-C -—,

65

—SO_.H. -—OSO3H. SH. —S(alkyl). —S(Valkenyl. and

haloalkyl. speci?cally including —CF3:

5.780.5l0
3
A=O or S: and
O,

Z is a C1 to C6 straight. branched. alkyl or cyclic group:

l

and
Y is a tert-butyl group that can be hydroxylated or
acetylated at one or more positions: phenyl or

$0311

(R2),

and its pharmaceutically acceptable salts.
In a second aspect. the invention provides parenterally-.

e.g. intravenou sly- and orally-adrninistrable pharmaceuticzd
compositions having this compound or its salt as active

ingredient.

PBN was stated to be the most preferred compound at that

In a third aspect. this invention provides a method for

time. being said to have no measurable effect on normal or
uninjured cells. and a number of derivatives were also stated

treating a patient who is su?’ering from a condition involving

to be useful. including hydroxy derivatives. especially 2-. 3
or 4-hydroxyphenyl t-butyl nitrone and phenyl (mono-. di
or trihydroxy) tert-butyl nitrone: PBN esters. especially

ceutical composition based on this compound or its salt is

esters which release 2-. 3-. or 4-hydroxyphenyl t-butyl
nitrone such as acetoxy derivative; 2-. 3-. or

acute oxidative damage to the central nervous system. such
as a patient who has suffered a stroke. in which a pharma

administered parenterally. e.g. intravenously.
20

protracted low grade oxidative stress upon the central ner
vous system and progressive loss of central nervous system

4-carboxyphenyl t-butyl nitrone; phenyl hydroxybutyl
nitrone; alkoxyl derivatives. especially alkoxyl derivatives
which release 2-. 3-. or 4-hydroxyphenyl t-butyl nitrone. for
example. the 2-. 3-. or 4-methoxyphenyl derivatives of PBN:
and acetamide derivatives. especially acetamide derivatives
which release 2-. 3-. or 4-arninophenyl t-butyl nitrone;

diphenyl nitrone (PPN) and the analogous diphenyl nitrone
derivatives; N-tert-butyl-ot-(4-nitro-phenyl) nitrone; and
N-tert-butyl-ot-(2-sulfophenyl) nitrone.

In a fourth aspect. this invention provides a method for

treating a patient suffering from a condition characterized by
function. In this method. a pharmaceutical composition

25

based on this compound or its salt is administered

parenterally. e.g. intravenously or preferably orally.
In a ?fth aspect. this invention provides a method for

reducing or ameliorating the side-effects arising from oxi
dative damage produced in a patient by cancer therapy. In
30

this method a pharmaceutical composition based on this
compound or its salt is administered parenterally. e.g. intra

venously or orally.
DETAILED DESCRIPTION OF THE
INVENTION

STATEMENT OF THE INVENTION
35

It has now been discovered that one particular PBN

This Detailed Description is arranged into the following
sections:

derivative and its salts have unexpectedly superior pharma

cological properties. Although this derivative. 2.4-disulfo

Brief Description of Drawings.

PBN. falls Within the broad family of materials generally
described in the aforementioned W0 92/022290 publication.
it is not speci?cally disclosed Neither are its advantageous

The Compounds and Salts.

Compound Preparation.
Pharmaceutical Compositions.

properties predicted.

Conditions Treated and Treatment Regimens.

Examples.
The present compound with its two sulfonate groups was
expected to exhibit improved water solubility but was also
expected to exhibit poor transport across the blood/brain
barrier because of its lipophobic character. However. when
the present compound was made and tested in vivo. it
showed an unexpected increase in e?icacy as compared to
PBN. This increase in e?icacy occurred along with an
increase in potency as compared to PBN. In direct contrast
to this marked increase in potency and e?icacy there was a
marked and highly signi?cant decrease in toxicity as com
pared to PBN.

45

panying drawings in which
FIG. 1 is a schematic ?ow chart of the reactions used to

prepare the compound.
FIGS. 2 (A. B and C) and 3 (A. B. C. and D) are two sets

of graphs illustrating the undesirable change in animal body
55

These results were unexpected because in the general

literature on structure/activity relationships within speci?c
de?ned families of compounds therapeutic potency typically
covaries with toxicity. Thus. most related compounds main
tain their ratio of therapeutic potency to toxicity. In contrast.
the compound of this invention deviates from this expected
relationship when its potency increased and its toxicity
decreased relative to closely related analogs.
65

Accordingly. in one aspect. the invention provides the

PBN-disulfonyl compound

BRIEF DESCRIPTION OF THE DRAWINGS
In this speci?cation reference will be made to the accom

thermal regulatory ability which occurs as a function of dose
level with a prior art nitrone radical trapping agent and
contrasting this with the lack of such undesired toxic effect
with the compound of the invention.
FIG. 4 (A. B. C. and D) is a set of four graphs demon

strating the superiority of the compound of the invention as
compared to a closely related prior art nitrone compound in
the treatment of gradual neurodegeneration conditions (such
as Alzheimer’s disease) as illustrated by their relative ability
to interfere with beta amyloid protein‘s inactivation of key
enzymes in solution.
FIG. 5 is a graph illustrating the effectiveness of the
compound of the invention in reducing the ultimate infarct
volume observed following middle cerebral artery occlusion
in rats.

5.780.510
5

6

FIGS. 6 (A. B and C) are three graphs illustrating the
ability of the compound of the invention to reduce the
side-effects in animals of high dose levels of anticancer

with a slight excess of the amine being used. This reaction
can be carried out at similar temperature conditions. This

reaction is generally complete in 10 to 24 hours.

agents.

The product so formed is the free acid and is characterized

by a molecular weight of 89 g/mole. It is a white powdery
material which decomposes upon heating. It is characterized
by a solubility in water of greater than 1 gram/ml and a 1H
NMR spectrum in D20 of 8.048 ppm (dd. 8.4. 1.7 Hz): 8.836
ppm (d. 8.4 Hz); 8.839 ppm (d. 1.7 Hz): 8.774 ppm (s).
The various salts can be easily formed by admixing the
free acid in aqueous medium with two equivalents of the

THE COMPOUND AND SALTS

The compound of this invention is 2.4—disulfonyl
ot-phenyl tertiary butyl nitrone. It is also referred to infor
mally herein as “2.4-disulfon PBN” or “PBN 2.4
disulfonate." It exists in an acid form

appropriate base. for example. KOH for the potassium salt.
and the like.

PHARMACEUTICAL COMPOSITIONS
The compound (including its salts) can be formulated into
pharmaceutical compositions suitable for oral or parenteral.
e.g. intravenous or intramuscular injection administration.
as a solid and in solution in low pH conditions. It also exists
at higher pHs in an ionized salt form which can be shown as 20
The compositions for oral administration can take the

form of liquid solutions or suspensions. powders. tablets.
capsules or the like. In such compositions. the PBN 2.4
disulfonate or its salt is usually a minor component (0.1 to
25

say 50% by weight) with the remainder being various
vehicles or carriers and processing aids helpful for forming
the desired dosing form. A liquid form may include a
suitable aqueous or nonaqueous vehicle with buffers. sus

pending dispensing agents. colorants. ?avors and the like.
A solid form may include. for example. any of the
30

where X is a pharmaceutically acceptable cation. Most
commonly. this cation is a monovalent material such as
sodium. potassium or ammonium. but it can also be a
multivalent cation alone or in combination with a pharma

following ingredients. or compounds of a similar nature: a
binder such as microcrystalline cellulose. gum tragacanth or
gelatin; an excipient such as starch or lactose. a disintegrat
ing agent such as alginic acid. Primogel. or corn starch; a
lubricant such as magnesium stearate; a glidant such as
35 colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint. sugar.

methyl salicylate. or orange ?avoring.
In the case of injectable compositions. they are commonly
based upon injectable sterile saline or phosphate-buffered
saline or other injectable carriers known in the art. Again the

ceutically acceptable monovalent anion. for example cal

active nitrone is typically a minor component. often being
from about 0.05 to 10% by weight with the remainder being
the injectable carrier and the like.

cium with a chloride. bromide. iodide. hydroxyl. nitrate.
sulfonate. acetate. tartrate. oxalate. succinate. palmoate or

the like anion; magnesium with such anions; zinc with such
anions or the like. When these combinations of a polyvalent 45
cation and a monovalent anion are illustrated in structural

formulae. herein. the monovalent anion is identi?ed as “Y”.

Among these materials. the free acid and the simple
sodium. potassium or ammonium salts are most preferred

with the calcium and magnesium salts also being preferred

50

but somewhat less so.

COMPOUND PREPARATION
As detailed in FIG. 1 and demonstrated in Example 1. the
compound of this invention can be prepared by a two step
reaction sequence. In the ?rst step. commercially available

55

tertiary butyl nitrate (Z-methyLZ-nitropropane) is converted
to the corresponding n-hydroxyl amine using a suitable
catalyst such as an activated zinc/acetic acid catalyst or an

aluminum/mercury amalgam catalyst. This reaction can be
carried out in 0.5 to 12 hours and especially about 2 to 6
hours or so at a temperature of about 15° to 100° C. in a

Conditions Treated and Treatment Regimens
The conditions treated with the 2.4.disolfo PBN generally
fall into three groups. The ?rst includes conditions involving
acute intense oxidative damage to a region of the central
nervous system. Examples of these conditions include
stroke. conditions associated with stroke. concussion and
subarachnoid hemorrhage. In this setting. the compound is
administered in a manner designed to get the drug into the
patient’s bloodstream as quickly and directly as possible.
This usually means intravenous administration.
Intravenous dose levels for treating these conditions range
from about 0.1 mg/kg/hour to at least 10 mg/kg/hour. all for
from about 1 to about 120 hours and especially 24 to 96
hours. A preloading bolus of from about 10 to about 500 mg
may also be administered to achieve adequate steady state
levels.
While intravenous administration is preferred. other

liquid reaction medium such as alcohol/water mixture in the

forms of parenteral administration. such as intramuscular

case of the zinc catalyst or an ether/water mixture in the case

injection can be used. as well. In this case. similar dose

of the aluminum amalgam catalyst.
In the second step. the freshly formed hydroxylamine is
reacted with 4-formyl-1.3-benzenedisulfonic acid. typically

65

levels are employed. An unexpected and key advantage of
2.4.disulfo PBN is that it can be administered at vastly
higher levels than are possible with PBN itself. As will be

5.7805 l0
7
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shown in the Examples. doses of up to 1000 mg/kg/hour and
higher or intravenous bolus doses of from 10 to 2500 mg/kg
have been demonstrated to be possible with 2.4.disulfo PBN

administer large amounts of 2.4.disulfo PBN such as those
described above for the acute intense oxidative CNS damage
conditions. In other settings lower doses. such as those set

or its salts while with PBN itself death or acute toxicity
results from such doses. _With 2.4.disulfo PBN there is an

forth for the progressive neuronal disease therapy. may be
used.
The following are examples of representative administra

unexpected positive continuance of the dose/response curve
in these high dose levels with the clear message that intense
heavy dosing immediately post stroke or other trauma may
in many cases provide a major positive impact upon recov
cry.

tion regimens: In monotherapy (adriamycin alone) two
representative dose combinations are 10-600 mg Compound
I per square meter area plus 60 mg adriamycin per square
meter of surface area with adriamycin dosing occurring
every seven or twenty-one days. Compound I may be
administered before the adriamycin. for example. up to 60

The second group of conditions which respond favorably
to 2.4.disulfo PBN treatment are conditions characterized by
protracted low grade oxidative stress upon the central ner

minutes before. at the same time or after. such as hours after

vous system and gradual progressive central nervous system

and on subsequent days. The pediatric dose is typically

function loss. These conditions include Alzheimer's disease.

lower for both drugs. Higher doses may be used for treat

Parkinson’s disease. arnyotrophic lateral sclerosis (ALS).
multi-infarct dementia. retinopathy and the like. Each of
these conditions is characterized by a progressive loss of

ment of multidose resistant tumors.

function. 2.4-disulfonyl-PBN or its salts. when administered
orally or parenterally. e.g. intravenously. can slow and
possibly reverse the loss of function. If parenteral. e.g.
intravenous administration is desired. similar levels to those
used with acute conditions but at the lower end of the ranges
are generally used.
In these cases. the regimen for treatment may stretch over
many months or years so oral dosing is preferred for patient
convenience and tolerance. With oral dosing. one to three
oral doses per day. each from about 0.02 to about 50 mg/kg
are called for with preferred doses being from about 0.04 to

about 5.0 mg/kg.

EXAMPLES

Example 1

20

Synthesis of 2.4-disulfophenyl-N-t-butylnitrone
(Compound “I” in subsequent Examples). This preferred
synthesis is based on the work by R. H. Hinton and E. G.
25

Janzen (J. Org. Chem. 57:2646-2651. 1992). As shown in
FIG. 1 it involves the condensation of an aldehyde with a

hydroxylamine. The hydroxylamine is unstable and is pre
pared fresh on the day of use using an activated zinc catalyst.
The synthesis is as follows:

Prerequisite Chemicals

30

Of course. one can administer 2.4-disu1fonyl PBN as the

. 95% Ethanol

sole active agent or one can administer it in combination
with other agents. This leads to a third application for this

compound.
A third set of conditions which respond to treatment with
2.4.disulfo PBN are the side-etfects which arise in patients

35

6. Saturated sodium chloride

damage causing chemotherapeutic agents. Examples of

9. Methanol
l0. Dichloromethane

rubicin and bleomycin; procarbazine; nitrogen mustards
45

Administration of 2.4.disulfo PBN can have the effect of

50

and the advantages of providing maximum possible protec
tion or amelioration. it may be desired in some settings to

1. A 500 ml three neck round bottom ?ask is equipped
with a magnetic stir bar. thermometer adapter.
thermometer. and addition funnel.
2. 95% ethanol (350 ml) was added to the ?ask and cooled
to 10° C. in an ice bath.

3. 2-Methyl-2-nitropropane (6.18 g. 0.060 mole). and zinc
dust (5.89 g. 0.090 mole) were added in single portions.
55

4. Glacial acetic acid (10.8 g. 0.180 mole) was placed in
the addition funnel and added dropwise at such a rate

with vigorous stirring to maintain the temperature
below 15° C.
5. The ice bath was removed and mixture was stirred for
3 hrs at room temperature.

A positive dose-response relationship has been observed
As such. and bearing in mind the severity of the side effects

Procedure

A. Preparation of N-t-Butylhydroxylamine

reducing patient discomfort during these therapies. In

cases these side effects are devastatingly destructive and
lead to heart failure and other major function loss. In tests in
animals it has been observed that the compound of the
invention can improve patient tolerance of these antine
oplastic disease treatments.
In this therapy. the compound of the invention may be
administered before. during and after the radiation or che—
motherapy is administered. Administration may be
parenteral or oral or by any other method which will permit
the 2.4-disulfonate PBN to enter the patient’s bloodstream.

4. Glacial acetic acid

7. Magnesium Sulfate. Anhydrous solid
8. 4-Formyl-1.3-benzenesulfonic acid (MW 310.21
g/mole). disodium salt. hydrate

these agents include antibiotics such as daunorubicin. doxo

addition. administration of the compound of this invention
can increasing patients‘ ability to tolerate these therapies.
Often the side effects of therapies force the discontinuance
of these therapies or prevent the administration of optimal
high doses or rapid frequencies of these therapies. In some

. 2-Methyl-2-nitropropane
. Zinc dust

5. Diethyl ether

from oxidative damage produced by cancer (neoplastic
disease) therapy. The therapy which produces the oxidative
damage (and thus the side effects) includes radiation (e.g.
gamma radiation) therapy and therapy with oxidative

such as ifosfarnide. melphalan and chlorambucil; alkylating
agents; antimetabolites; hormones and antagonists.

LAN’

65

6. The solvent was stripped from the mixture. leaving
t-butylhydroxylarnine. zinc acetate. and water.
7. Dichloromethane (50 ml) was added and the mixture
?ltered through a Buchner funnel.
8. The zinc acetate cake left on the ?lter paper was washed
with 2x25 ml dichloromethane.

5.780.510
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2. The ?ask was ?tted with a 250 ml pressure-equalizing
dropping funnel. a mechanical stirrer. a nitrogen inlet.
and a Friedrichs condenser cooled with recirculated ice

9. Water was separated from the ?ltrate in a separatory

funnel and the organic layer dried over magnesium
sulfate.

water.

10. The magnesium sulfate was removed by ?ltering
through ?uted ?lter paper. then dichloromethane

3. The mixture was stirred for 10 minutes.

stripped o? by rotary evaporation.

4. 2~Methyl-2-nitropropane (71.68 g. 75.5 ml) was added
using the dropping funnel at such a rate as to maintain

11. The product (100% yield=5.34 g). a viscous liquid.

a vigorous re?ux.
NOTE: Addition must be completed in less than 20
minutes or the yield drops signi?cantly.

was dissolved in methanol (50 ml) for use in part B.

B. Preparation of 2.4-disulfonylphenyl-N-t-butylnitrone
1. A 3-neck 250 ml round bottom ?ask was set up with a
stir bar. a gas dispersion tube. an addition funnel. and

5. As the addition proceeded. ether was added in 500 ml
portions. This was done to maintain as high a concen—

a Friedrichs condenser cooled with recirculating ice

tration of product as possible without the formation of

water.

2. To the ?ask were added 200 ml of methanol. 4-formyl

15

1.3-benzenedisulfonic acid (9.31 g. 30 mmoles) and
N-t-butylhydroxylamine (25 ml of the methanol solu
tion from part A. 30 mmoles theoretical).
3. The reaction was heated to re?ux with a heating mantle

while bubbling the reaction with nitrogen with stirring.

20

7. The resulting gray suspension was suction ?ltered in 3
batches to remove aluminum salts.

4. The mixture was re?uxed for 2 hours.

8. Each ?lter cake was washed with l l of ether.
9. The combined either layers were washed with 300 ml

5. The remainder of hydroxylamine from part A was
added.

of 2M NaOH. then dried (M gSO4). and concentrated in

6. Re?uxing was continued with nitrogen bubbling for at

25
least 18 hours. but not more than 24 hours.
7. The hot reaction mixture was ?ltered on a Buchner

vacuo to leave a soft white solid.

10. The solid melts just above room temperature. but
could be dried further in a vacuum oven (no more than

funnel. and the solid washed with hot methanol.
8. The methanol was stripped off by rotary evaporation to
a yellow. viscous oil.
9. Hot 1:1 ethanolzacetone (200 ml) was added and the

a few minutes). leaving 38 to 45 g of solid.
11. The solid can be used as is or was puri?ed by

recrystallization from pentane.
12. Molecular weight—89 g/mole.
B. Preparation of 2.4-disulfonylphenyl-N-t-butylnitrone

mixture heated to dissolve the oil.
10. The solution was cooled to crystallize the product.

1. A 250 ml ?ask was equipped with a stir bar and a

11. The product was collected on a Buchner funnel and

dried under vacuum overnight.

a gel. Up to 2 l of ether can be added with no deleterious
e?ects on the yield.
6. Once addition of 2-methyl-2-nitropropane was
complete. the reaction was stirred for an additional 30
minutes.

35

Friedrichs condenser cooled with recirculated ice
water.

12. The reaction typically gives 75% yield of Compound

2. The ?ask was charged with 71.8 ml of methanol. 14.5

I. a white powder.

g of 4-formyl-1.3-benzenedisulfonic acid (46.7
mmoles. 1 eq.). and 5.0 g of N-t-butylhydroxylamine

Example 2
Alternate Synthesis of 2.4-disulfonylphenyl-N-t
butylnitrone (Compound I). This is an earlier-developed
method which used to prepare samples of the compound
used in several of the experiments reported in the Examples
of this speci?cation. The product of this Example is identical
in all ways to the product of Example 1. This synthesis

(56.2 mmoles. 1.2 eq.).
b) . The mixture was re?uxed overnight.
4. The reaction product was transferred to round-bottom

?ask and rotovaped to dry.
45

method is as follows:

Prerequisite Chemicals
1. Aluminum Foil. cut into 5 cm wide strips and rolled in

5. The solid residue was mashed with ether. the ether was

decanted off (yellow).
6. Step 5 was repeated.
7. Product (“Compound I”) was crystallized from metha
nol following a hot methanol ?ltration to remove

a ca. 1 cm diameter cylinder

insoluble precipitates and recrystallized twice from

2. Mercury (II) Chloride (9.68 g in 476 ml water)

methanol.

3. Ethanol

Example 3

4. Ether (6 l)

A series of experiments were carried out to compare in

5. Pure Water

6. 2-Methyl-2-nitropropane
7. Sodium Hydroxide. 2M (80 g in 11 water)

8. Magnesium Sulfate. Anhydrous solid
9. 4-Formyl-1.3-benzenesulfonic acid (MW 310.21

g/mole)

55

vivo the e?icacy of 2.4 disulfo PBN (“Compound I"). PBN.
and two monosulfonate PBN compounds as agents for

protecting against neuron loss following brain ischemia and
reperfusion injury. The test procedure is that reported by W.
Cao. J. M. Carney. A. Duchon. R. A. Floyd and M. Chevion
as “Oxygen free radical involvement in ischemia and rep

Procedure

A. Preparation of N-t-Butylhydroxylamine
1. Aluminum foil cylinders were dipped into HgCl2
solution for 15-30 seconds. then dipped in ethanol.
then dipped in ether and then placed into a 5 l ?ask
containing 500 ml of diethyl ether and 21.4 ml of water.

erfusion injtu'y to brain. Neuroscience Letters, 88 (1988).
233. In the experiments a test compound was administered
to groups of six gerbils i.p. as a single dose 30 min before
5 min bilateral carotid occlusion. The density of neuronal
65 nuclei in a 100 micron was measured. Two controls were

present—controls which received no test compound and
controls which received no test compound and no brain

5.780.510
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ischemia. As illustrated in Table l. the compound of the
invention showed unexpected advantages as compared to the
prior an compounds. First. it is seen that at low dose levels.
such as 3.2 mg/kg. compound I is 2-3 times as potent at
preventing neuronal loss. At high dose levels it is seen that

TABLE 2-continued
Neuronal nuclei/100 micron field
5

2-

3-

PBN

srlfo

sulfo

I

320 rug/kg

2.25

0.81

0.93

3.55

(.43)

(.31)

1000 lug/kg

Toxic

ND

ND

3.68

Compound I is able to achieve complete protection against
neuronal loss as the test brains showed neuronal densities
identical to the non-ischemic controls. The prior art com
pounds are either toxic at these dose levels or showed

signi?cantly lower degrees of protection. These results show

Cmpd.

(.48)

(.39)

a clear increase in potency for neural protection for com

pound I compared to PBN and two closely related analogs
and an unexpected decrease in toxicity compared to PBN.

Example 5
Compound I is compared with PBN to determine the
relative e?ectiveness for protection of neuronal loss when
administered i.v. 60 min after reperfusion onset following 5

TABLE 1
Neuronal nuclei/100 micron ?eld

2PBN
Non-ischemic control

sul

3-

Cmpd.

sulfo

I

4.21

4.21

4.21

(.43)

(.43)

(.43)

(.43)

Ischemic control

0.58

0.58

0.58

0.58

(.28)

(.28)

(.28)

(.28)

3.2 mgfkg

0.43

0.73

0.35

1.43

(.18)

(.34)

(.21)

(.31)

0.68

0.81

min ischemia in gerbils using the general test method
described in Example 1.. The results are summarized in
20

4.21

1O rug/kg

1.13

(.39)

(.31)

(.40)

(.25)

32 mg/kg

1.83

0.73

1.63

3.53

(.21)

(.31)

(.35)

(.41)

SOmg/kg

3.11

1.01

1.63

4.11

(.29)

(.61)

(.35)

(.43)

100 mg/kg

3.68

0.93

1.93

4.18

(.71)

(.53)

(.39)

(.49)

320 mg/kg

3.78

1.11

1.78

4.23

(.43)

(.41)

(.40)

(.39)

1000 mg/lrg

Toxic

0.98

1.58

4.11

(.43)

(.38)

3200 mg/kg

Toxic

——

—

Table 3. and illustrate that compound I is of signi?cantly
greater therapeutic bene?t in a clinical treatment setting
following injury to the brain.
TABLE 3

25

2.57

N = 6 per group

mg/kg single dose
0.0

Saline. no ischemia

0.5

4.11

1.0

10

—

—

—

—

—

—

0.83

1.07

1.23

(.23)

(.29)

(.31)

1.25

1.75

2.43

(.19)

(.28)

(.31)

(.23)
30

saline, ischemia

0.93

(J7)
PBN

Compound I

—

—

(.41)
35

4.18

Neither PBN nor Compound I. had an e?ect on neuronal

density in control gerbils without brain injury.

Example 4

Example 6

A series of experiments were conducted in which com

Brain injury can manifest itself as behavioral changes. In

pound Iwas compared to PBN and two sulfonate analogs in
post-ischemia treatment. The general method described in

this experiment. young adult (3-4 months of age) gerbils
were tested to determine their ability to perform an S-arm

example 1 was used but the test compounds were adminis

tered i.p. as a single dose 30 min after reperfusion following
5 min ischemia. The results are summarized in Table 2.
Table 2 shows that the compound of the invention is again

maze test 24 hours following an ischemic event as described
45

more potent at low doses and more potent and less toxic at

the prior art compounds to go to high doses at which levels
.

.

.

.

_

untreated they committed many more errors. PBN and
compound I were administered to some of the test animals.

As detailed in Table 4. gerbils treated with high doses of
compound I had error levels indistinguishable from those of

high doses. Also again. toxicity interferes with the ability of

the compound of the 1nvent1on provides dramatically effec
ave therapy‘

in Example 1. As compared to nonischemic animals. when

50

nonischemie animals. PBN was less etfective. This shows
'

that compound I can protect against thg loss of temporal]
spatial short term memory following ischemia (24 hours
post) errors in 8-arm radial maze test of young gerbils

TABLE 2

following 5 min ischemia.

Neuronal nuclei/100 micron ?eld

55

TABLE 4
2.
PBN

3-

Cmpcl.

sul

sulfo

I

4.18

4.18

Non-ischemic control

4.18
(.59)

(.59)

(.59)

(.59)

Ischemic control

0.85

0.85

0.85

0.85

(.19)

(.19)

(.19)

(.19)

32 mg/kg

109

ND

ND

1.83

SOmg/kg

1.85

0.68

0.73

2.73

(.49)

(.31)

(.34)

(.39)

2.11

0.78

1.09

3.41

(.51)

(.23)

(.48)

(.37)

(.31)

100 mg/kg

N = 6 per group

4.18
60

Control

mg/kg/hr for 24 hours
0.0

1.0

4.1

_

32
-

50

100
_

—

~

_

(.38)
Postischemic

37.6

(4.85)

(.41)

PBN

CompoundI

65

_

_

29.8

18.19

6.23

(7.27)

(5.83)

(.71)

5.83

(.49)

14.63

7.19

4.28

4.11

(3.81)

(.81)

(.29)

(.19)

5.780.510
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Example 7

as high as 1000 mg/kg with no measurable temperature
decrease. In contrast. the compound of the art. PBN. gave up
to an 8° C. decrease in body temperature at a does of only

The ability of the compound of the invention to reduce
infarct volume following an ischemic event was determined.
As detailed in Table 5. it was observed that while PBN and

500 mg/kg.
Example ll

compound I were both eifective at low doses. at high doses
I gave the best protection and PBN was toxic. Table 5 shows
the infarct volume observed when test compound was
administered iv. 60 min after middle cerebral occlusion and
continued for 24 hours in C57BL/6] mice.

The compound of the invention was tested to determine
its effectiveness in the treatment of conditions characterized

by protracted low grade oxidative stress upon the central
nervous system and gradual progressive central nervous
system function loss by testing its e?ectiveness in a model
for Alzheimer’s disease (“AD"). This model has the follow

TABLE 5

ing basis: Recent studies have demonstrated that there is an

age-associated increase in protein oxidation and loss of

Infarct Volume in mm3
Posttreatment
Control, no ischemia
Saline, ischemia

10

enzyme activities in the brain of aged individuals. Tissue
cultures of ?broblasts from aged individuals and red blood
cells of different ages both show an exponential increase in

0.0

1.0

100

0

—

-

—

23

—

—

—

protein carbonyl content (a measure of protein oxidation)

13.8

Toxic

and a decrease in marker enzyme activities. Brain protein
oxidation progressively increases over the life span of the

(2)
PEN

—

17.7

(2.8‘)

(2.3)

Compound I

-—

16.8

12.7

8.3

(1.7)

(3.93)

(.71)

20

Example 8

25

In this study. compound I and PBN are compared for their

infused into rat brains. lesions are produced. Some of the

ability to impart lethality protection (% survived) in aged

proposed breakdown fragments of [SAP are also neurotoxic
[c.g. PAP (25-35)|. The neurotoxicity appears to be both
mediated via glutamate receptors. and also by non-glutamate

gerbils (18-24 months of age. n=l2/group) from 10 rnin
ischemia when given 30 min before ischemia. As shown in
Table 6. compound I is superior at all dose levels and

receptors mechanisms. Confocal microscopy studies of neu
ronal cultures have demonstrated that exposure to [SAP
(1-40) results in oxidative stress [Dichloro?uorescein and
increased intracellular free calcium Fura-Z}.
It has been demonstrated that BAP fragments can directly

achieved complete protection at high levels while PBN is

only partially e?‘ective.
TABLE 6
35

Pretreatment

0.0

10

32

MI)

320

PBN

—

—

—

—

—

42

50

75

Compound I

—

50

92

75

100

100

the dose-related inactivation of glutamine synthetase and
creatine kinase by AP (25-35). (brtosolic fractions from
gerbil neocortex were prepared and enzyme activities deter
mined. Sarnples were incubated in the presence of different
concentrations of the peptide for 10 min prior to assay. Solid

Example 9

symbols represent the effects of the naturally occurring

An important advantage of the compound of this inven
tion as compared to the art-taught compound. PBN. is its
markedly diminished toxicity. As detailed in Table 7. acute
lethality in C57BL/6L mice was determined based upon

45

also had no effect on enzyme activities. compared to the

radicals are an important determinant of the initiation and

showed no toxicity at doses nearly twenty times as great.

progression of AD.

TABLE 7

Ins/ks
320

560

1000

3000

10000

55

n = Z) mice

PBN

100

25

O

0

0

Compound l

100

I00

100

100

100

this invention was administered to mice and gerbils at levels

As demonstrated in C and D in FIG. 4. compound I and
PBN each show the ability to protect GS and CK against the
effects of BAP fragments. C and D of FIG. 4 present the
protective effects of co-incubation of the cytosolic fractions
with BAP 25-35 (0.4 mg/ml) in combination with djtferent
concentrations of PBN (open circles) or compound I (closed
circles). Each point is the mean (+/- s.e.) of 3 observations.
As can be seen in C and D. compound I gives complete
protection and in fact might even be able to reverse the
effects of oxidation. In contrast. PBN‘s effectiveness is quite
limited as it is asymptotically leveling out at a substantially

Example 10
Another undesirable systemic e?‘ect which has been
observed in vivo with nitrone radical traps is a depression in
body temperature. This toxicity can have serious health
consequences and also can complicate diagnosis of other
conditions. As detailed in FIGS. 2 and 4. the compound of

25-35 fragment. Open circles indicate that the reverse
sequence (32-25) had no effect on enzyme activity. Open
triangles indicate that the scrambled amino acid sequence

effect of 25-35. Each point is the mean (+/— s.e.) of 5
observations. BAP derived and other cellular sources of free

varying sizes of single i.p. doses of nitrone. PBN showed
signi?cant toxicity at 560 mg/kg dose levels. Compound I

% Survival

inactivate glutamine synthetase (GS) and creatine kinase
(CK) in tissue extracts and in cultured hippocampal neurons
and glia (See A and B in FIG. 4). A and B of FIG. 4 present

(mg/kg)
Saline

individual.
The role of abnormal amyloid precursor peptide process
ing and metabolism in AD has also been explored in a
number of ditferent models. In vitro studies using embryonic
hippocarnpal neuronal and neuronal/glia] cultures have dem
onstrated that BAP l-40 produces cytotoxicity over an
extended period of co-incubation. When this peptide is

incomplete level of protection.
Example 12
65

Experiments were carried out to further demonstrate the

e?ectiveness of the compound of the invention in preventing
central nervous system damage caused by stroke.

5.780.5l0
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Rat Focal Ischernia Results

these tests was found to be 25 mg/kg in both mouse strains.

Compound I doses up to 300 mg/kg. without adriamycin

A pair of studies were done to determine the ef?cacy of
Compound I in a rat focal ischemia model. In this model.
Sprague Dawley rats (200-300 g) underwent a permanent
middle cerebral artery occlusion (MCAO) to induce a focal
stroke. Compound I was administered after the permanent
occlusion as ?rst an intraperitoneal (i.p.) bolus dose and then

treatment. had no effect on survival in the two mouse strains.

Pretreatment with 30 and 100 mg/kg of Compound I
produced dose related shifts in the adriamycin lethality dose
effect curve. FIG. 6 shows the results obtained using the
DEA/2] mouse. A dose of 100 mgkg of Compound I
produced a 5-fold shift to the right (in the direction of

by intravenous (i.v.) continuous infusion during the remain
ing time up to 24 hours post stroke. The doses of Compound
I used were either 100 mg/kg. i.p.. followed by 4.2 mg/kg/hr.
i.v.. or 10 mg/kg. i.p.. followed by 0.42 mgkg/hr. iv.

reduced lethality). Thus. the combination of Compound I
with adriamycin resulted in a marked increase in the maxi
mally tolerated dose. These higher doses are in the range that

would effectively kill multi-drug resistant tumors.

The rats were sacri?ced 3 days post stroke. the tissue was

processed histologically using triphenyltetrazolium staining

Comparative Tests

techniques. and the infarct volume. the area of total cell

PBN pretreatment resulted in a slight shift to the right in
the adriamycin does-e?’ect curve. While the Compound I
dose could be increased to 300 mg/kg in combination with
adriamycin. there was an upper limit for this combination

necrosis. was quantitated using image analysis. The results
of these experiments are shown graphically in FIG. 5 and

demonstrate that Compound I provided signi?cant
protection. approximately 70%. in both studies.
Comparison with Results in the Literature.
Similar data have been reported recently for the com
pound NOI‘ of this invention. PBN. by Cao and Phillis
(Brain Research 664: 267-272. 1994). In their studies. rats
underwent a permanent middle cerebral artery occlusion

20

with PBN. A dose of PBN of 100 mg/kg produced slight
sedation and 300 mg/kg yielded marked sedation and some

combined toxicity (IO-20% lethality). Compound
Iladriamycin did not produce any combined toxicity at doses
of Compound I of up to 300 mg/kg.

Example 14

25

(MCAO) and a common carotid artery occlusion. The PBN
was administered i.p. at 100 mg/kg at various times post
stroke. The rats were sacri?ced 2 days post stroke and the

Safety Testing.
Compound I and PBN were tested for their acute toxicity

infarct volume was quantitated using triphenyltetrazolium

in male Sprague Dawley (200-300 g) rats. The compounds

of Compound I required for 70% protection. Thus. Com
pound I is far superior to PBN in offering protection in the

effective concussion treating amount of a pharmaceutical

were administered at 1000 mg/kg. i.p.. to groups of 6 rats.
stain.
30
After 3 days lethality was assessed. Compound I caused no
When PBN was administered at 0.5. 5. 17. 29 and 41
lethality. while PBN was lethal to 5 of the 6 rats used in this
hours post stroke. or at 5. 17. 29. and 41 hours post stroke.
test. These data con?rm the gerbil data in that Compound I
the infarct volume was reduced in each case by approxi
has higher safety than PBN.
mately 50%. The cumulative dose of PBN administered to
What is claimed is:
achieve 50% protection is at a minimum 4 times the amount 35
1. A method for treating a patient who has suffered a

concussion comprising administering to said patient an

rat MCAO focal ischcrnia model.

composition comprising the compound 2.4-disulfo alpha
phenyl tertiary butyl nitrone in a pharmaceutically accept

Example 13

able carrier.

In this Example the compound of this invention
(Compound I) was evaluated to determine its ability to

2. The method of claim 1 wherein the composition is

administered parenterally.

ameliorate oxidation-caused side e?rects of anticancer

therapy.

3. The method of claim 2 wherein the composition is
45

Adriamycin Studies
Adn'amycin is a widely used anticancer agent. It is known
50

limited the use of this agent or limited the dose levels that
can be employed to levels which are below those desired for

maximum antineoplastic disease effectiveness.

4. The method of claim 3 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.
5. The method of claim 1 wherein the composition is

administered orally.

to be very effective but it is also known to have serious side

effects arising from its tendency to cause oxidative damage.
These side effects include causing serious levels of cardiac
damage at high dose levels. These side effects have often

administered intraveneously.

6. A method for treating a patient who has suffered a

concussion comprising administering to said patient an
e?’ective concussion treating amount of a pharmaceutical
composition comprising a compound of the formula:

55

Experiments were carried out to demonstrate that the

compound of the invention is effective at reducing the side
effects of anticancer agents such as adriamycin and permit
ting higher dose levels of adriamycin to be tolerated by
animals.
C57B1J6J and DBA/2J male mice (35-40 g) were tested

for the acute lethal elfects of adriamycin and the prevention

in a pharmaceutically acceptable carrier.
7. The method of claim 6 wherein the composition is

of acute le?iality by pretreatment doses of Compound I.

administered parenterally.

Mice were injected with either saline or Compound I 30

minutes prior to administration of adriamycin. All injections
were intraperitoneal. The acute lethality of adriamycin
ranged from 10 to 30 mg/kg. The LDS0 for adriamycin in

8. The method of claim 7 wherein the composition is
65

administered intraveneously.
9. The method of claim 8 wherein the composition is
administered in an amount of at least 0.2 mgkg/hour.

5.780.510
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10. The method of claim 6 wherein the composition is

administered orally.
11. A method for treating a patient who has sulfered a

concussion comprising administering to said patient an
e?ective concussion treating amount of a pharmaceutical

composition comprising a pharmaceutically acceptable salt

50311

of:

in a pharmaceutically acceptable carrier.
27. The method of claim 26 wherein the composition is

administered parenterally.
28. The method of claim 27 wherein the composition is

administered intraveneously.
29. The method of claim 28 wherein the composition is

in a pharmaceutically acceptable carrier.
12. The method of claim 11 wherein the composition is

15

administered in an amount of at least 0.2 mg/kg/hour.

30. The method of claim 26 wherein the composition is

administered orally.

administered parenterally.

31. A method for treating a patient who is sulfering from
a subarachnoid hemorrhage comprising administering to
said patient an e?‘ective subarachnoid hemorrhage treating
amount of a pharmaceutical composition comprising a phar

13. The method of claim 12 wherein the composition is

administered intraveneou sly.
14. The method of claim 13 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.

maceutically acceptable salt of:

15. The method of claim 11 wherein the composition is

administered orally.
16. A method for treating a patient who has suffered a

concussion comprising administering to said patient an
effective concussion treating amount of a pharmaceutical
composition comprising a compound of the formula:
30

in a pharmaceutically acceptable carrier.
32. The method of claim 31 wherein the composition is

administered parenterally.
33. The method of claim 32 wherein the composition is
35

wherein X is selected from the group consisting of Na. K.
N114. Ca. Mg. Zn. ZnY. CaY and MgY. wherein Y is a
pharmaceutically acceptable monovalent anion. in a phar

administered intraveneously.
34. The method of claim 33 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.

35. The method of claim 31 wherein the composition is

administered orally.

maceutically acceptable carrier.

36. A method for treating a patient who is suifen'ng from
a subarachnoid hemorrhage comprising administering to
said patient an elfective subarachnoid hemorrhage treating

17. The method of claim 16 wherein the composition is

administered parenterally.
18. The method of claim 17 wherein the composition is

amount of a pharmaceutical composition comprising a com

administered intraveneously.

pound of the formula:

19. The method of claim 18 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.
20. The method of claim 16 wherein the composition is

0

administered orally.
21. A method for treating a patient who is suffering from
a subarachnoid hemorrhage comprising administering to
said patient an effective subarachnoid hemorrhage treating
amount of a pharmaceutical composition comprising the

compound 2.4-disulfo alpha-phenyl tertiary butyl nitrone in
a pharmaceutically acceptable carrier.
22. The method of claim 21 wherein the composition is

administered parenterally.
23. The method of claim 22 wherein the composition is

administered intraveneously.
24. The method of claim 23 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.

50

wherein X is selected from the group consisting of Na. K.
NR4. Ca. Mg. Zn. ZnY. CaY and MgY. wherein Y is a
pharmaceutically acceptable monovalent anion. in a phar

maceutically acceptable carrier.
37. The method of claim 36 wherein the composition is

administered parenterally.
38. The method of claim 37 wherein the composition is

administered orally.

administered intraveneou sly.
39. The method of claim 38 wherein the composition is

26. A method for treating a patient who is su?ering from
a subarachnoid hemorrhage comprising administering to
said patient an effective subarachnoid hemorrhage treating

administered orally.

25. The method of claim 21 wherein the composition is

amount of a pharmaceutical composition comprising a com

pound of the formula:

administered in an amount of at least 0.2 mg/kgfhour.

40. The method of claim 36 wherein the composition is

